Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Chiauranib |
Synonyms | |
Therapy Description |
Chiauranib (CS2164) is a multi-kinase inhibitor that inhibits AURKB, CSF-1R, VEGFRs, KIT, and PDGFRA, resulting in decreased tumor growth and angiogenesis (PMID: 28004478, PMID: 30642372). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Chiauranib | CS2164 | Aurkb Inhibitors 21 CSF1R Inhibitor 28 KIT Inhibitor 57 PDGFR-alpha Inhibitor 9 VEGFR Inhibitor (Pan) 36 | Chiauranib (CS2164) is a multi-kinase inhibitor that inhibits AURKB, CSF-1R, VEGFRs, KIT, and PDGFRA, resulting in decreased tumor growth and angiogenesis (PMID: 28004478, PMID: 30642372). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02122809 | Phase I | Chiauranib | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | Completed | 1 | |
NCT05271292 | Phase Ib/II | Chiauranib | Chiauranib for Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Recruiting | USA | 0 |